BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

4055

531349

PANACEABIO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Panacea Biotec performance

Today’s low

Today’s high

₹ 441.50 ₹ 452.00
₹ 446.50

52 week low

52 week high

₹ 277.50 ₹ 581.90
₹ 446.50

Open Price

₹ 446.35

Prev. Close

₹ 450.85

Volume (Shares)

77062.00

Total traded value

₹ 344.08

Upper Circuit

₹ 541.00

Lower Circuit

₹ 360.70

info

Panacea Biotec Share Price Update

As of the latest trading session, Panacea Biotec share price is currently at ₹ 448, which is down by ₹ -2.85 from its previous closing. Today, the stock has fluctuated between ₹ 441.50 and ₹ 452.00. Over the past year, Panacea Biotec has achieved a return of 31.94 %. In the last month alone, the return has been 3.76 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Panacea Biotec fundamentals


  • Market cap (Cr)

    2,734.80

  • P/E Ratio (TTM)

    -338.98

  • Beta

    1.06

  • Book Value / share

    47.72

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -6.70

info icon alternate text
  • Market cap (Cr)

    2,727.50

  • P/E Ratio (TTM)

    -338.98

  • Beta

    0.98

  • Book Value / share

    47.72

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -6.70

info icon alternate text

Panacea Biotec Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 112.25
Operating Expense 126.04
Net Profit -6.70
Net Profit Margin (%) -5.96
Earnings Per Share (EPS) -1.09
EBITDA 1.92
Effective Tax Rate (%) 24.20
Particulars MAR 2025 (Values in Cr)
Revenue 67.90
Operating Expense 96.02
Net Profit -12.39
Net Profit Margin (%) -18.24
Earnings Per Share (EPS) -2.02
EBITDA -12.48
Effective Tax Rate (%) 43.75
Particulars DEC 2024 (Values in Cr)
Revenue 108.43
Operating Expense 102.10
Net Profit 9.65
Net Profit Margin (%) 8.89
Earnings Per Share (EPS) 1.58
EBITDA 18.71
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 76.64
Operating Expense 78.75
Net Profit 1.29
Net Profit Margin (%) 1.68
Earnings Per Share (EPS) 0.21
EBITDA 10.14
Effective Tax Rate (%) 0.76
Particulars JUN 2024 (Values in Cr)
Revenue 56.88
Operating Expense 75.66
Net Profit -13.78
Net Profit Margin (%) -24.22
Earnings Per Share (EPS) -2.25
EBITDA -6.68
Effective Tax Rate (%) 8.01
Particulars MAR 2025 (Values in Cr)
Revenue 309.85
Operating Expense 352.53
Net Profit -15.23
Net Profit Margin (%) -4.91
Earnings Per Share (EPS) -2.49
EBITDA 9.69
Effective Tax Rate (%) 41.55
Particulars MAR 2024 (Values in Cr)
Revenue 359.60
Operating Expense 380.29
Net Profit 3.55
Net Profit Margin (%) 0.98
Earnings Per Share (EPS) 0.58
EBITDA 39.08
Effective Tax Rate (%) 15.67
Particulars MAR 2023 (Values in Cr)
Revenue 257.07
Operating Expense 354.25
Net Profit -87.54
Net Profit Margin (%) -34.05
Earnings Per Share (EPS) -14.29
EBITDA -28.18
Effective Tax Rate (%) -39.50
Particulars MAR 2022 (Values in Cr)
Revenue 235.50
Operating Expense 341.65
Net Profit -93.58
Net Profit Margin (%) -39.73
Earnings Per Share (EPS) -15.28
EBITDA -60.10
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 343.56
Operating Expense 377.15
Net Profit -14.44
Net Profit Margin (%) -4.20
Earnings Per Share (EPS) -2.35
EBITDA 21.24
Effective Tax Rate (%) -12.14
Particulars MAR 2025 (Values in Cr)
Book Value / Share 132.76
ROE % -5.13
ROCE % -4.31
Total Debt to Total Equity 0.02
EBITDA Margin -0.77
Particulars MAR 2024 (Values in Cr)
Book Value / Share 133.94
ROE % -3.52
ROCE % -2.84
Total Debt to Total Equity 0.02
EBITDA Margin 1.90
Particulars MAR 2023 (Values in Cr)
Book Value / Share 134.20
ROE % -11.06
ROCE % -9.50
Total Debt to Total Equity 0.03
EBITDA Margin -11.22
Particulars MAR 2022 (Values in Cr)
Book Value / Share 139.59
ROE % -60.80
ROCE % -5.11
Total Debt to Total Equity 1.32
EBITDA Margin -0.34
Particulars MAR 2021 (Values in Cr)
Book Value / Share -40.87
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 13.64
Particulars MAR 2025 (Values in Cr)
Book Value / Share 47.72
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.52
EBITDA Margin 3.13
Particulars MAR 2024 (Values in Cr)
Book Value / Share 50.20
ROE % 0.86
ROCE % 3.26
Total Debt to Total Equity 0.32
EBITDA Margin 10.86
Particulars MAR 2023 (Values in Cr)
Book Value / Share 49.63
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.24
EBITDA Margin -10.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 64.24
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.16
EBITDA Margin -25.52
Particulars MAR 2021 (Values in Cr)
Book Value / Share 79.43
ROE % -2.53
ROCE % -1.10
Total Debt to Total Equity 0.09
EBITDA Margin 5.22
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 106.96
Total Assets 1289.74
Total Liabilities 1289.74
Total Equity 830.61
Share Outstanding 61250746
Price to Book Ratio 9.23
Return on Assets (%) -0.64
Return on Capital (%) -0.98
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 122.00
Total Assets 1240.82
Total Liabilities 1240.82
Total Equity 838.22
Share Outstanding 61250746
Price to Book Ratio 2.42
Return on Assets (%) -0.09
Return on Capital (%) -0.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 225.99
Total Assets 1271.16
Total Liabilities 1271.16
Total Equity 840.11
Share Outstanding 61250746
Price to Book Ratio 2.18
Return on Assets (%) -2.61
Return on Capital (%) -3.86
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 583.27
Total Assets 1758.86
Total Liabilities 1758.86
Total Equity 873.65
Share Outstanding 61250746
Price to Book Ratio 2.31
Return on Assets (%) 61.30
Return on Capital (%) 118.78
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 135.79
Total Assets 1177.53
Total Liabilities 1177.53
Total Equity -231.69
Share Outstanding 61250750
Price to Book Ratio 2.23
Return on Assets (%) -12.54
Return on Capital (%) -25.13
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 62.16
Total Assets 869.46
Total Liabilities 869.46
Total Equity 313.96
Share Outstanding 61250746
Price to Book Ratio 9.23
Return on Assets (%) -1.75
Return on Capital (%) -2.81
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 11.95
Total Assets 753.79
Total Liabilities 753.79
Total Equity 329.14
Share Outstanding 61250746
Price to Book Ratio 2.42
Return on Assets (%) 0.47
Return on Capital (%) 0.78
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 43.25
Total Assets 723.90
Total Liabilities 723.90
Total Equity 325.65
Share Outstanding 61250746
Price to Book Ratio 2.18
Return on Assets (%) -12.09
Return on Capital (%) -20.45
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 42.68
Total Assets 761.83
Total Liabilities 761.83
Total Equity 415.09
Share Outstanding 61250746
Price to Book Ratio 2.31
Return on Assets (%) -12.28
Return on Capital (%) -18.74
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 88.96
Total Assets 790.28
Total Liabilities 790.28
Total Equity 508.16
Share Outstanding 61250750
Price to Book Ratio 2.23
Return on Assets (%) -1.82
Return on Capital (%) -2.52
Particulars MAR 2025 (Values in Cr)
Net Income -7.94
Cash from Operations -26.40
Cash from Investing 64.98
Cash from Financing -2.66
Net change in Cash 34.95
Free Cash Flow 23.90
Particulars MAR 2024 (Values in Cr)
Net Income 1.47
Cash from Operations 5.97
Cash from Investing 6.65
Cash from Financing -2.80
Net change in Cash 7.31
Free Cash Flow 88.85
Particulars MAR 2023 (Values in Cr)
Net Income 12.80
Cash from Operations -419.97
Cash from Investing 430.33
Cash from Financing -18.37
Net change in Cash -10.49
Free Cash Flow -379.02
Particulars MAR 2022 (Values in Cr)
Net Income 1449.35
Cash from Operations 295.25
Cash from Investing 1282.57
Cash from Financing -1175.85
Net change in Cash -1.72
Free Cash Flow 307.76
Particulars MAR 2021 (Values in Cr)
Net Income -145.03
Cash from Operations 107.75
Cash from Investing -47.67
Cash from Financing -47.11
Net change in Cash 11.97
Free Cash Flow 129.52
Particulars MAR 2025 (Values in Cr)
Net Income -26.05
Cash from Operations 5.04
Cash from Investing -60.60
Cash from Financing 90.07
Net change in Cash 33.41
Free Cash Flow 58.01
Particulars MAR 2024 (Values in Cr)
Net Income 4.20
Cash from Operations 34.95
Cash from Investing -46.80
Cash from Financing 12.81
Net change in Cash -0.91
Free Cash Flow 110.47
Particulars MAR 2023 (Values in Cr)
Net Income -62.75
Cash from Operations -9.65
Cash from Investing 2.41
Cash from Financing 9.00
Net change in Cash 0.67
Free Cash Flow 28.72
Particulars MAR 2022 (Values in Cr)
Net Income -93.57
Cash from Operations -51.86
Cash from Investing 39.54
Cash from Financing 9.82
Net change in Cash -3.32
Free Cash Flow -43.81
Particulars MAR 2021 (Values in Cr)
Net Income -12.88
Cash from Operations 39.24
Cash from Investing -37.32
Cash from Financing -7.20
Net change in Cash -6.25
Free Cash Flow 53.78
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.14 13.53 1.81 253.96 30.00 / 68.00
BLISS GVS PHARMA LTD 152.65 15.13 1.53 1612.74 105.05 / 190.65
CIPLA LTD 1568.65 23.50 4.06 126710.17 1310.05 / 1611.10
FERMENTA BIOTECH LIMITED 269.55 7.59 2.18 793.31 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.14 18.01 5.23 253.96 30.00 / 68.00
AMRUTAJAN HEALTH LTD 695.80 36.89 6.15 2011.60 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9098.20 107.56 29.52 22745.50 6222.35 / 10653.05
BLISS GVS PHARMA LTD 152.65 22.85 1.52 1612.74 105.05 / 190.65

Panacea Biotec shareholding pattern

Holding

Others
25.21%
Promoter Holdings
72.47%
FII
0.78%
DII
1.52%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Dr. Rajesh Jain 3.0217312E7 (49.33%) Shareholding of Promoter and Promoter Group
Mr. Sandeep Jain 9351924.0 (15.27%) Shareholding of Promoter and Promoter Group
Mrs. Nirmala Jain 2511000.0 (4.1%) Shareholding of Promoter and Promoter Group
First Lucre Partnership Co. 2255815.0 (3.68%) Shareholding of Promoter and Promoter Group
Second Lucre Partnership Co. 57639.0 (0.09%) Shareholding of Promoter and Promoter Group
Mr. Ashish Jain 500.0 (0.0%) Shareholding of Promoter and Promoter Group
Mr. Abhey Kumar Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sandeep Jain (huf) (karta: Sandeep Jain) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajesh Jain (huf) (karta: Rajesh Jain) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrs. Priyanka Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mr. Harshet Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mr. Ankesh Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrs. Radhika Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mr. Sumit Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrs. Pamilla Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrs. Meena Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrs. Sunanda Jain 0.0 (0.0%) Shareholding of Promoter and Promoter Group

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

Panacea Biotec Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
446.50 -0.96 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 445.10
  • 26 Days 428.30
  • 10 Days 438.00
  • 50 Days 425.50
  • 12 Days 435.90
  • 100 Days 426.50
  • 20 Days 430.60
  • 200 Days 409.70
452.62 PIVOT

First Support

441.23

First Resistance

462.23

Second Support

431.62

Second Resistance

473.62

Third Support

420.23

Third Resistance

483.23

RSI

62.49

ADX

34.63

MACD

7.69

Williams % R

-18.55

Commodity Channel Index (CCI)

114.43

Date

2025-10-16

Week

91212.00

Same Day

115096.00

Month

105551.00

1 Year

1.07

3 Year

0.87

Over 1 Month

3.76%

down

Over 1 Year

31.94%

down

Over 3 Months

4.15%

down

Over 3 Years

47.41%

down

Over 6 Months

-9.47%

down

Over 5 Years

19.93%

down

Panacea Biotec Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2011 0.75 Final 21 Sep 2011 Equity shares
16 Sep 2010 0.25 Final 20 Sep 2010 Equity shares
19 Sep 2008 1.0 Final 23 Sep 2008 Equity shares
21 Sep 2007 1.0 Final 25 Sep 2007 Equity shares
12 Aug 2005 0.0 Final 17 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
03 Feb 2003 10.0 1.0 11 Feb 2003
Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2011 0.75 Final 21 Sep 2011 Equity shares
16 Sep 2010 0.25 Final 20 Sep 2010 Equity shares
19 Sep 2008 1.0 Final 23 Sep 2008 Equity shares
21 Sep 2007 1.0 Final 25 Sep 2007 Equity shares
12 Aug 2005 0.0 Final 17 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
03 Feb 2003 10.0 1.0 11 Feb 2003

Panacea Biotec Share Price

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Limited. The name of the Company was changed to the present 'Panacea Biotec Limited' in 1993.

A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines.

The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997, the company obtained its first product patent in several countries. PBL's Research & Development made a tie up with European MNC in the year 2001 and in 2002, an in-licensing agreement was made with Biotechnology Consortium of India for development & commercialization of Anthrax Vaccine. Also in the identical year of 2002, the company had commissioned Recombinant Vaccine production plant. During the year 2004, PBL made an in-licensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine, marketing joint venture with Chiron (now Novartis) Vaccines, UK and also made collaboration with Cambridge Bio-stability, UK, for Thermo Stable Vaccines. After a year in 2005, an in-licensing agreement was prepared with National Institute of Health, USA for Hair Growth Hormone.

During the year 2006, ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh was goes live, which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute (The Nederlands Vaccin Institute (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture & market Measles Vaccine. Also in the same year of 2006, the company had inaugurated its Biopharmaceutical R&D Centre at New Delhi and made collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008, made a collaboration to set-up 220 bed multi super-specialty hospital in NCR and also the company obtained a patent (Patent No. 7,371,412 B2) from US Patent & Trademark Office for the product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles in the identical year of 2008.

During year 2008-09, Company's Joint Venture Company, Chiron Panacea Vaccines Pvt. Ltd. (CPV), set-up for marketing of innovative
combination and other vaccines in India has launched Hepatitis A vaccine HAVpur, in collaboration with Berna Biotech Ltd., Switzerland and the Company's Injectable Polio Vaccine 'PolProtec'and monohib Vaccine (novoHib) in the Indian market.

During the year 2008-09, the Company's associate firm, viz. M/s Lakshmi & The Manager, in which the Company had invested Rs.40 million (40% share), was taken over by a newly formed company, Lakshmi & Manager Holdings Limited. As a result of takeover of
the said firm, the Company has been allotted Equity Shares for an amount of Rs.41 .3 million in the said company.

The Company had launched generic product Tacrolimus in Germany in 2011 under the brand 'Tacpan' through Company's indirect wholly owned subsidiary company Panacea Biotec Germany GmbH (PBGG).

In 2013, Company's 50:50 joint venture Adveta Power Pvt. Ltd with its associate PanEra Biotec Pvt. Ltd, incorporated to generate and distribute power or any other energy from conventional / non-conventional energy sources on a commercial basis.

During the year 2013-14, the Company disposed of entire shareholding in its erstwhile WOS, Lakshmi & Manager Holdings Ltd. (LMH). Post such disposal, LMH and its WOS Trinidhi Finance Pvt. Ltd. and subsidiary Best General Insurance Company Ltd. ceased to be the subsidiaries of the Company w.e.f. 25 January, 2014.

During the year 2015, the Company launched new products in various therapeutic categories including: Glizid M V ( Voglibose, Gliclaz ide & Metformin Hydrochloride)- Anti-diabetic; Calcom Plus (Coral Calcium, Vitamin D3 & Vitamin K2-7)- Orthopedic segment and RF Willgo (Paracetamol and Aceclofenac)- Pain management and To Plus (Paracetamol etc.) -Anti-cold.

During 2016, Company introduced India's first indigenously developed high quality Oncology product, CABAPAN (Cabazitaxel) Injection, for treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC). Further, it introduced indigenously anti-diabetic drug, TENEPAN (Teneligliptin), for treatment of Type 2 Diabetes Mellitus (T2DM). In December 2016, it launched world's first fully liquid tetravalent vaccine, Easyfour-TT for active primary immunization and booster dose against Diphtheria, Tetanus, Pertussis (DTwP) and Haemophilus Influenza Type B (Hib).

In March, 2017, it launched first liquid whole cell pertussis (wP) based Hexavalent Combination vaccine, EasySixTM. The Company had one subsidiary, viz. NewRise Healthcare Private Limited, which consequently ceased to be subsidiary of the Company effective from April 21, 2017.

The Board of Directors of the Company had, at its meeting held on May 30, 2019 approved the Scheme of Arrangement between the Company and Ravinder Heights Limited (RVHL) and their respective shareholders and creditors for demerger of real estate business of the Company comprising of Radhika Heights Limited along with its step down subsidiaries and two real estate properties, into RVHL, which was approved from April 01, 2019 and the Scheme became effective from September 10, 2020.

During the current year 2020, Radhika Heights Limited (RHL) along with its step down subsidiaries and two real estate properties, were demerged into RVHL and RHL and its subsidiaries have ceased to be the subsidiary of the Company w.e.f. September 10, 2020.

During the FY 2019-20, the Company transferred its pharmaceutical formulations business including pharmaceutical formulations facility at Baddi and related research & development and natural products extraction activities at Lalru, to its wholly owned subsidiary
viz. Panacea Biotec Pharma Limited (PBPL) by way of slump sale on going concern basis, which completed with effect from February 1, 2020.

As on March 31, 2021, Panacea Biotec Pharma Limited (PBPL ) became a material subsidiary of Company.

The Company and PBPL entered into definitive agreements on February 28, 2022 for sale of Pharmaceutical Formulations Brands
of PBPL in India and Nepal to Mankind Pharma Limited at an aggregate consideration of Rs.18,720 million. As part of this arrangement, Mankind retained PBPL's well-trained sales and marketing team engaged in the pharmaceutical formulations business and said
transaction was completed on March 3, 2022.

During the year 2024, Company launched world's first fully liquid wP-IPV based Pentavalent Vaccine, EasyFourPol@. Company's wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL) launched the nanotechnology-based generic product, Paclitaxel protein bound in human albumin particles. The Phase III clinical trial for DengiAllr in adults, was initiated in August 2024.

Valgapan (Valganciclovir) launched in Germany in FY 2025. Company scaled ChilRunr brands to over 10,000 retail outlets in India in FY 2025.

Parent organization Indian Private
NSE symbol PANACEABIO
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Panacea Biotec Ltd?

Answer Field

Panacea Biotec Ltd share price is for NSE ₹ 448.00 & for BSE ₹ 444.65 as on Oct 17 2025 03:29 PM.

What is the Market Cap of Panacea Biotec Ltd Share?

Answer Field

The market cap of Panacea Biotec Ltd for NSE ₹ 2,744.03 & for BSE ₹ 2,723.51 as on Oct 17 2025 03:29 PM.

What is the 52 Week High and Low of Panacea Biotec Ltd?

Answer Field

The 52 Week High and Low of Panacea Biotec Ltd for NSE is ₹ 581.90 and ₹ 277.50 and for BSE is ₹ 581.00 and ₹ 278.40.

What is 1 year return for Panacea Biotec Ltd?

Answer Field

The 1 year returns on the stock has been 31.94%.

What is the P/E Ratio of Panacea Biotec Ltd Share?

Answer Field

As on Oct 17 2025 03:29 PM the price-to-earnings (PE) ratio for Panacea Biotec Ltd share is -338.98.

What is the PB ratio of Panacea Biotec Ltd Share?

Answer Field

As on Oct 17 2025 03:29 PM, the price-to-book (PB) ratio for Panacea Biotec Ltd share is 47.72.

How to Buy Panacea Biotec Ltd Share?

Answer Field

You can trade in Panacea Biotec Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Panacea Biotec Ltd Share on Bajaj Broking App?

Answer Field

To buy Panacea Biotec Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Panacea Biotec Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59